Cancer Innovations Inc., Eisai deal

Eisai's Morphotek Inc. subsidiary received an option for exclusive, worldwide rights to Cancer Innovations' undisclosed mAbs targeting tumor-associated proteins. Morphotek has an undisclosed period t...